Suppr超能文献

关爱使用致畸性皮肤科药物的育龄期女性。实践指南。

Caring for women with childbearing potential taking teratogenic dermatologic drugs. Guidelines for practice.

作者信息

Perlman S E, Rudy S J, Pinto C, Townsend-Akpan C

机构信息

Department of Obstetrics and Gynecology, University of Louisville School of Medicine, Louisville, Kentucky, USA.

出版信息

J Reprod Med. 2001 Feb;46(2 Suppl):153-61.

Abstract

Upon completion of this article, the reader should be able to: 1. Identify the dermatologic drugs with the highest risk of teratogenicity. 2. List the essential information to be obtained from a woman with childbearing potential being considered for treatment with a teratogenic dermatologic agent. 3. Discuss management principles for administration of teratogenic agents to women with childbearing potential. Dermatologic agents can be highly teratogenic, and the gynecologist must be aware of the issues involved in prescribing them. Prescribers should be aware of the risks and ensure that patients taking teratogens do not become pregnant during the course of therapy (or until the drug has been cleared from the body). This can involve taking menstrual and sexual histories and counseling the patient about sexual behavior and contraception.

摘要

读完本文后,读者应能够:1. 识别致畸性风险最高的皮肤科药物。2. 列出从有生育潜力且考虑用致畸性皮肤科药物治疗的女性那里应获取的基本信息。3. 讨论对有生育潜力的女性使用致畸性药物的管理原则。皮肤科药物可能具有高度致畸性,妇科医生必须了解开具此类药物所涉及的问题。开处方者应知晓风险,并确保服用致畸药物的患者在治疗期间(或直到药物从体内清除)不会怀孕。这可能涉及询问月经史和性史,并就性行为和避孕问题向患者提供咨询。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验